Cargando…

Erythrocytosis associated with EPAS1(HIF2A), EGLN1(PHD2), VHL, EPOR or BPGM mutations: the Mayo Clinic experience

Detalles Bibliográficos
Autores principales:	Gangat, Naseema, Oliveira, Jennifer L., Porter, Tavanna R, Hoyer, James D., Al-Kali, Aref, Patnaik, Mrinal M, Pardanani, Animesh, Tefferi, Ayalew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052925/ https://www.ncbi.nlm.nih.gov/pubmed/35142155 http://dx.doi.org/10.3324/haematol.2021.280516

Ejemplares similares

JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views
por: Gangat, Naseema, et al.
Publicado: (2021)

Low incidence of EPOR mutations in idiopathic erythrocytosis
por: Filser, Mathilde, et al.
Publicado: (2020)

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
por: Tefferi, Ayalew, et al.
Publicado: (2023)

Expansion of EPOR-negative macrophages besides erythroblasts by elevated EPOR signaling in erythrocytosis mouse models
por: Wang, Jieyu, et al.
Publicado: (2018)

Characterization of genetic variants in the EGLN1/PHD2 gene identified in a European collection of patients with erythrocytosis
por: Delamare, Marine, et al.
Publicado: (2023)

Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
por: Gangat, Naseema, et al.
Publicado: (2023)

Mayo Clinic experience with 1123 adults with acute myeloid leukemia
por: Begna, Kebede H., et al.
Publicado: (2021)

Congenital erythrocytosis – discover of a new mutation in the EGLN1 gene
por: Barradas, João, et al.
Publicado: (2018)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Isolated Erythrocytosis Associated With 3 Novel Missense Mutations in the EGLN1 Gene
por: Moore, Joseph A., et al.
Publicado: (2020)

Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
por: Ilyas, Rimal, et al.
Publicado: (2023)

Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis
por: Mudireddy, Mythri, et al.
Publicado: (2018)

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Mast cell sarcoma: 2 Mayo Clinic cases
por: Singh, Amritpal, et al.
Publicado: (2022)

Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?
por: Nicolosi, Maura, et al.
Publicado: (2018)

Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates
por: Shah, Sahrish, et al.
Publicado: (2017)

The role of PHD2 mutations in the pathogenesis of erythrocytosis
por: Gardie, Betty, et al.
Publicado: (2014)

The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis
por: Hudler, Petra, et al.
Publicado: (2022)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022)

U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions
por: Tefferi, Ayalew, et al.
Publicado: (2018)

A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy
por: Gangat, Naseema, et al.
Publicado: (2019)

P580: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
por: Basmaci, Rami, et al.
Publicado: (2023)

Clinical characteristics of a Turkish family with congenital erythrocytosis due to an EPOR mutation: Is routine phlebotomy indicated in children and adolescents?
por: Sarper, Nazan, et al.
Publicado: (2020)

Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
por: Nicolosi, Maura, et al.
Publicado: (2018)

MPL-mutated essential thrombocythemia: a morphologic reappraisal
por: Szuber, Natasha, et al.
Publicado: (2018)

Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience
por: Katamesh, Bahga, et al.
Publicado: (2022)

An Erythrocytosis-Associated Mutation in the Zinc Finger of PHD2 Provides Insights into Its Binding of p23
por: Song, Daisheng, et al.
Publicado: (2019)

P734: CLONAL HEIRARCHY AND HETEROGENEITY IN STAG2M MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
por: Katamesh, Bahga, et al.
Publicado: (2023)

Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases
por: Gangat, Naseema, et al.
Publicado: (2022)

Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience
por: Begna, K, et al.
Publicado: (2016)

P722: CHARACTERISATION OF PHF6 MUTATIONS IN MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
por: Sai Mittapalli, Amrutha, et al.
Publicado: (2023)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
por: Gangat, Naseema, et al.
Publicado: (2023)

P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
por: Oum, Muhamad, et al.
Publicado: (2023)

Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q)
por: Tefferi, Ayalew, et al.
Publicado: (2017)

Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points
por: Gangat, Naseema, et al.
Publicado: (2020)

To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022)

PB2043: ERYTHROCYTOSIS IN PATIENTS WITH TIBETAN EGLN1C127S MUTATION: IS IT A POLYMORPHISM IN PATIENTS LIVING AT SEA LEVEL?
por: Biagetti, G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gboofuakmsd2d5thvn5b18gk3a